India, Nov. 10 -- NeurAxis Inc. (NRXS), a medical technology company, reported financial results for the third quarter, noting an increased loss despite higher sales due to higher expenses.
The company specializes in developing neuromodulation therapies for chronic and debilitating conditions. Its flagship product is IB-Stim, a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology marketed for the treatment of irritable bowel syndrome (IBS) and functional dyspepsia.
Q3 Financial Results:
Net loss for the third quarter ascended to $6.54 million, considerably higher than the loss of $2.12 million was recorded in the same period of 2025.
The company attributed this to one-time, non-recurring stock compensation charges amountin...